Induction of a pathological complete response by four courses of neoadjuvant chemotherapy for gastric cancer: Early results of the randomized phase II COMPASS trial

Annals of Surgical Oncology

Volumn 21, Issue 1, 2014, Pages 213-219

  Yoshikawa, Takaki ^a   Tanabe, Kazuaki ^b   Nishikawa, Kazuhiro ^c   Ito, Yuichi ^d   Matsui, Takanori ^d   Kimura, Yutaka ^e   Hirabayashi, Naoki ^f   Mikata, Shoki ^g   Iwahashi, Makoto ^h   Fukushima, Ryoji ⁱ   Takiguchi, Nobuhiro ^j   Miyashiro, Isao ^k   Morita, Satoshi ^l   Miyashita, Yumi ^m   Tsuburaya, Aakira ^a   Sakamoto, Junichi ⁿ  

^a KANAGAWA CANCER CENTER   (Japan)

^b HIROSHIMA UNIVERSITY   (Japan)

^c OSAKA GENERAL MEDICAL CENTER   (Japan)

^d AICHI CANCER CENTER HOSPITAL   (Japan)

^e OSAKA POLICE HOSPITAL   (Japan)

^f HIROSHIMA CITY ASA HOSPITAL   (Japan)

^g OSAKA ROSAI HOSPITAL   (Japan)

^h WAKAYAMA MEDICAL UNIVERSITY   (Japan)

ⁱ TEIKYO UNIVERSITY   (Japan)

^j CHIBA CANCER CENTER   (Japan)

^k OSAKA MEDICAL CENTER FOR CANCER AND CARDIOVASCULAR DISEASES   (Japan)

^l YOKOHAMA CITY UNIVERSITY MEDICAL CENTER   (Japan)

^m Nonprofit Organization   (Japan)

ⁿ NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR; PACLITAXEL;

ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; ADULT; AGED; ALOPECIA; ANEMIA; ARTICLE; BONE MARROW TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; FATIGUE; FEMALE; HUMAN; HYPERKALEMIA; LOSS OF APPETITE; MALE; MIDDLE AGED; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; STOMACH CANCER; VERY ELDERLY; VOMITING;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; DRUG COMBINATIONS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM STAGING; OXONIC ACID; PACLITAXEL; PROGNOSIS; STOMACH NEOPLASMS; SURVIVAL RATE; TEGAFUR; YOUNG ADULT;

EID: 84891741070     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-013-3055-x     Document Type: Article

References (33)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127:2893-917.
2. Yoshikawa T, Sasako M. Gastrointestinal cancer: adjuvant chemotherapy after D2 gastrectomy for gastric cancer. Nat Rev Clin Oncol. 2012;9:192-94.
3. Association TJGC. Japanese gastric cancer treatment guidelines 2010 (ver 3). Gastric Cancer. 2011;14:113-23.
4. Sakuramoto S, Sasako M, Yamaguchi T, Kinoshita T, Fujii M, Nashimoto A, et al. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med. 2007;357:1810-20.
5. Bang YJ, Kim YW, Yang HK, Chung HC, Park YK, Lee KH, et al. Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial. Lancet. 2012;379(9813):315- 21.
6. Sasako M, Sakuramoto S, Katai H, Kinoshita T, Furukawa H, Yamaguchi T, et al. Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer. J Clin Oncol. 2011;29:4387-93.
7. Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJ, Nicolson M, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006;355:11-20.
8. Okines A, Verheij M, Allum W, Cunningham D, Cervantes A. Gastric cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2010;21(Suppl 5):v50-4.
9. Ychou M, Boige V, Pignon JP, Conroy T, Bouche O, Lebreton G, et al. Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. J Clin Oncol. 2011;29:1715-21.
10. Ng K, Meyerhardt JA, Fuchs CS. Adjuvant and neoadjuvant approaches in gastric cancer. Cancer J. 2007;13:168-74.
11. Koizumi W, Narahara H, Hara T, Takagane A, Akiya T, Takagi M, et al. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol. 2008;9:215-21.
12. Takahari D, Hamaguchi T, Yoshimura K, Katai H, Ito S, Fuse N, et al. Feasibility study of adjuvant chemotherapy with S-1 plus cisplatin for gastric cancer. Cancer Chemother Pharmacol. 2011;67:1423-8.
13. Kodera Y, Ishiyama A, Yoshikawa T, Kinoshita T, Ito S, Yokoyama H, et al. A feasibility study of postoperative chemotherapy with S-1 and cisplatin (CDDP) for gastric carcinoma (CCOG0703). Gastric Cancer. 2010;13:197-203.
14. Inoue K, Nakane Y, Kogire M, Fujitani K, Kimura Y, Imamura H, et al. Phase II trial of preoperative S-1 plus cisplatin followed by surgery for initially unresectable locally advanced gastric cancer. Eur J Surg Oncol. 2012;38:143-9.
15. Nashimoto A, Yabusaki H, Nakagawa S, Takii Y, Tsuchiya Y, Otsuo T. Preoperative chemotherapy with S-1 and cisplatin for highly advanced gastric cancer. Anticancer Res. 2009;29:4689-96.
16. Yoshikawa T, Omura K, Kobayashi O, Nashimoto A, Takabayashi A, Yamada T, et al. A phase II study of preoperative chemotherapy with S-1 plus cisplatin followed by D2/D3 gastrectomy for clinically serosa-positive gastric cancer (JACCRO GC-01 study). Eur J Surg Oncol. 2010;36:546-51.
17. Sakamoto J, Matsui T, Kodera Y. Paclitaxel chemotherapy for the treatment of gastric cancer. Gastric Cancer. 2009;12:69-78.
18. Nishikawa K, Morita S, Matsui T, Kobayashi M, Takeuchi Y, Takahashi I, et al. A randomized phase-II trial comparing sequential and concurrent paclitaxel with oral or parenteral fluorinated pyrimidines for advanced or metastatic gastric cancer. Gastric Cancer. 2012;15:363-9.
19. Tsuburaya A, Sakamoto J, Morita S, Kodera Y, Kobayashi M, Miyashita Y, et al. A randomized phase III trial of post-operative adjuvant oral fluoropyrimidine versus sequential paclitaxel/oral fluoropyrimidine; and UFT versus S1 for T3/T4 gastric carcinoma: the Stomach Cancer Adjuvant Multi-institutional Trial Group (Samit) trial. Jpn J Clin Oncol. 2005;35:672-5.
20. Nagata N, Kimura M, Hirabayashi N, Tuburaya A, Murata T, Kondo K, et al. Phase II study of weekly paclitaxel and cisplatin combination therapy for advanced or recurrent gastric cancer. Hepatogastroenterology. 2008;55:1846-50.
21. Tsuburaya A, Nagata N, Cho H, Hirabayashi N, Kobayashi M, Kojima H, et al. Phase II trial of paclitaxel and cisplatin as neoadjuvant chemotherapy for locally advanced gastric cancer. Cancer Chemother Pharmacol. 2013;71:1309-14.
22. Yoshikawa T, Sasako M, Yamamoto S, Sano T, Imamura H, Fujitani K, et al. Phase II study of neoadjuvant chemotherapy and extended surgery for locally advanced gastric cancer. Br J Surg. 2009;96:1015-22.
23. Yoshikawa T, Tsuburaya A, Morita S, Kodera Y, Ito S, Cho H, et al. A comparison of multimodality treatment: two or four courses of paclitaxel plus cisplatin or S-1 plus cisplatin followed by surgery for locally advanced gastric cancer, a randomized Phase II trial (COMPASS). Jpn J Clin Oncol. 2010;40:369-72.
24. Habermann CR, Weiss F, Riecken R, Honarpisheh H, Bohnacker S, Staedtler C, et al. Preoperative staging of gastric adenocarcinoma: comparison of helical CT and endoscopic US. Radiology. 2004;230:465-71.
25. Hasegawa S, Yoshikawa T, Shirai J, Fujikawa H, Cho H, Doiuchi T, et al. A prospective validation study to diagnose serosal invasion and nodal metastases of gastric cancer by multidetector-row CT. Ann Surg Oncol. 2013;20(6):2016-22.
26. Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials. 1989;10:1-10.
27. Sobin LH, Gospodarowicz MK, Witterkind CH. International Union Against Cancer (UICC) TNM classification of malignant tumors. 7th ed. Oxford: Wiley Blackwell; 2009.
28. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92:205-16.
29. Clavien PA, Barkun J, de Oliveira ML, Vauthey JN, Dindo D, Schulick RD, et al. The Clavien-Dindo classification of surgical complications: five-year experience. Ann Surg. 2009;250:187-96.
30. Wang LB, Teng RY, Jiang ZN, Hu WX, Dong MJ, Yuan XM, et al. Clinicopathologic variables predicting tumor response to neoadjuvant chemotherapy in patients with locally advanced gastric cancer. J Surg Oncol. 2012;105:293-6.
31. Mansour JC, Tang L, Shah M, Bentrem D, Klimstra DS, Gonen M, et al. Does graded histologic response after neoadjuvant chemotherapy predict survival for completely resected gastric cancer? Ann Surg Oncol. 2007;14:3412-8.
32. Yoshikawa T, Nakamura K, Tsuburaya A, Sano T, Mizusawa J, Katai H, et al. A phase II study of preoperative chemotherapy with S-1 (S) and cisplatin (P) followed by D3 gastrectomy for gastric cancer (GC) with extensive lymph node metastasis (ELM): survival results of JCOG0405. Presented at Gastrointestinal Cancers Symposium, San Francisco, CA, 2011.
33. Kodera Y, Ito S, Mochizuki Y, Ohashi N, Tanaka C, Kobayashi D, et al. Long-term follow up of patients who were positive for peritoneal lavage cytology: final report from the CCOG0301 study. Gastric Cancer. 2012;15:335-7.